40452-20-8

Basic information

• Product Name: 2-Phenanthrenecarboxylic acid
• Synonyms: 2-Phenanthrenecarboxylic acid;Phenanthrene-2-carboxylic acid
• CAS NO: 40452-20-8
• Molecular Formula: C₁₅H₁₀O₂
• Molecular Weight: 222.24
• Mol File: 40452-20-8.mol
• Article Data: 5

Chemical Properties

• Melting Point: 258.5-260 °C
• Boiling Point: 435.367 °C at 760 mmHg
• Flash Point: 194.794 °C
• Appearance: /
• Density: 1.305
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.743
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.20±0.30(Predicted)
• CAS DataBase Reference: 2-Phenanthrenecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Phenanthrenecarboxylic acid(40452-20-8)
• EPA Substance Registry System: 2-Phenanthrenecarboxylic acid(40452-20-8)

Safety Data

• Hazardous Substances Data: 40452-20-8(Hazardous Substances Data)

Usage

Description

2-Phenanthrenecarboxylic acid is an organic compound derived from the phenanthrene family, characterized by its unique structure and properties. It possesses a carboxylic acid functional group, which allows it to form various chemical bonds and participate in different reactions. 2-Phenanthrenecarboxylic acid has gained attention in the scientific community due to its potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
2-Phenanthrenecarboxylic acid is used as a positive and negative modulator of NMDA receptors for its potential therapeutic effects on neurological disorders. As a modulator, it can either enhance or inhibit the activity of NMDA receptors, depending on the specific compound and its interaction with the receptor. This dual functionality makes it a valuable candidate for the development of drugs targeting a range of neurological conditions, such as Alzheimer's disease, Parkinson's disease, and other cognitive impairments.

InChI:InChI=1/C15H10O2/c16-15(17)12-7-8-14-11(9-12)6-5-10-3-1-2-4-13(10)14/h1-9H,(H,16,17)

Upstream product

• 109-72-8 n-butyllithium 
• 60-29-7 diethyl ether 
• 62162-97-4 2-bromophenanthrene 
• 94540-85-9 ethyl phenanthrene-2-carboxylate 
• 5960-69-0 2-acetylphenanthrene 
• 6669-79-0 2-benzoylphenanthrene 
• 5329-89-5 2-acetyl-9,10-dihydrophenanthrene 
• 75-15-0 carbon disulfide 
• 7446-70-0 aluminium trichloride 
• 79-37-8 oxalyl dichloride 
• 85-01-8 phenanthrene 
• 5968-48-9 1-Phenanthren-1-yl-ethanone 
• 21351-21-3 phenanthrene-2-carbonitrile 
• 110356-77-9 2-propanoylphenanthrene 

Downstream Products

• 94540-85-9 ethyl phenanthrene-2-carboxylate 
• 858131-66-5 (+/-)-cis-PPDA 
• 104952-88-7 [1-Phenanthren-2-yl-meth-(E)-ylidene]-(4-tetradecyloxy-phenyl)-amine 
• 104931-69-3 (4-Dodecyloxy-phenyl)-[1-phenanthren-2-yl-meth-(E)-ylidene]-amine 
• 104984-85-2 (4-Decyloxy-phenyl)-[1-phenanthren-2-yl-meth-(E)-ylidene]-amine 
• 104931-68-2 (4-Nonyloxy-phenyl)-[1-phenanthren-2-yl-meth-(E)-ylidene]-amine 
• 104931-67-1 4-heptyloxy-N-(2-phenanthrylmethylene)aniline 
• 104931-66-0 (4-Heptyloxy-phenyl)-[1-phenanthren-2-yl-meth-(E)-ylidene]-amine 
• 104931-65-9 (4-Hexyloxy-phenyl)-[1-phenanthren-2-yl-meth-(E)-ylidene]-amine 
• 104952-87-6 (4-Pentyloxy-phenyl)-[1-phenanthren-2-yl-meth-(E)-ylidene]-amine 
• 104931-64-8 (4-Butoxy-phenyl)-[1-phenanthren-2-yl-meth-(E)-ylidene]-amine 
• 104931-63-7 [1-Phenanthren-2-yl-meth-(E)-ylidene]-(4-propoxy-phenyl)-amine 
• 104931-62-6 (4-Ethoxy-phenyl)-[1-phenanthren-2-yl-meth-(E)-ylidene]-amine 
• 104931-61-5 (4-Methoxy-phenyl)-[1-phenanthren-2-yl-meth-(E)-ylidene]-amine 

Relevant articles and documents

-

-

KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS

The present invention pertains to certain ketones and reduced ketones and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formulae: (1) (2) wherein: Ar1 is independently a biphenyl, phenanthryl, fluorenyl, or carbazolyl, and is optionally substituted; Ralk is independently a C2-10alkylene group, and is optionally substituted; -ORO, if present, is independently -OH or -ORK; -ORK, if present, is independently selected from: -O-RK1; -O-C(=O)RK2; -O-C(=O)ORK3; -O-S(=O)2ORK4; Q is independently -OH or -OROT; wherein: -OROT, if present, is independently selected from: -O-RE1; -O-C(=O)-RE2; -O-C(=O)-O-RE3; -O-C(=O)-O-SO3RE4; -O-C(=O)-O-(CH2)n-COORE5; -O-C(=O)-(CH2)n-NRN1RN2; -O-C(=O)-(CH2)n-NH-C(=O)RE6; -O-C(=O)-(CH2)n-C(=O)-NRN3RN4; -O-P(=O)(ORE7)(ORE8); -O-RPA; RPA, if present, is an organic group which incorporates a phosphonic acid group; with the proviso that if -OROT is -O-RE1, then RE1 is not a phenyl group substituted with a sulfonyl group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, or prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit osteoclast survival, formation, and/or activity, and to inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, aseptic loosening of prosthetic implants, and the like; and/or in the treatment of conditions associated with inflammation or activation of the immune system.

Glucocorticoid receptor modulators

The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides intermediates and processes for preparing these compounds. STR1

Properties of the Liquid Crystals formed by Certain 4-Alkoxy-N-(2-phenanthrylmethylene)anilines

The liquid crystal transition temperatures of twelve 4-alkoxy-N-(2-phenanthrylmethylene)anilines are reported and compared with those of corresponding members of similar homologous series of azomethines.Differences in liquid crytal thermal stability between comparable azomethines in which the -CH=N- linkage is reversed are discussed.